Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Drop in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a significant decline in short interest in February. As of February 15th, there was short interest totalling 57,300 shares, a decline of 67.1% from the January 31st total of 174,100 shares. Currently, 7.7% of the company’s stock are short sold. Based on an average trading volume of 148,900 shares, the days-to-cover ratio is currently 0.4 days.

Windtree Therapeutics Trading Down 0.9 %

Shares of Windtree Therapeutics stock opened at $3.44 on Friday. The stock has a fifty day simple moving average of $10.06 and a 200 day simple moving average of $95.68. Windtree Therapeutics has a 12-month low of $3.44 and a 12-month high of $737.43. The company has a market capitalization of $2.58 million, a P/E ratio of -0.21 and a beta of 0.54.

Windtree Therapeutics (NASDAQ:WINT) last announced its quarterly earnings results on Tuesday, November 26th. The company reported ($211.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($113.50) by ($98.00). On average, analysts predict that Windtree Therapeutics will post -5.66 EPS for the current year.

Hedge Funds Weigh In On Windtree Therapeutics

A hedge fund recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new position in Windtree Therapeutics, Inc. (NASDAQ:WINT) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned about 1.08% of Windtree Therapeutics as of its most recent SEC filing. 29.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating and set a $350.00 price target on shares of Windtree Therapeutics in a report on Wednesday, December 4th.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.